文献速递头颈部肿瘤放疗放疗物理与技术

放疗增强90Y-西妥昔单抗的摄取与疗效:一项临床前试验

Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial.
PubMed 文献 · Radiother Oncol · 2020-11-21

该临床前研究在FaDu头颈部鳞癌异种移植瘤小鼠中,用近红外标记西妥昔单抗活体成像观察不同分割放疗方案对 antibody 摄取的影响,并测试分割放疗(30次/6周)联合90Y-西妥昔单抗的肿瘤控制效果。结果显示低至中等外照射剂量可增强抗体摄取,优化方案下联合治疗较单纯放疗显著提高肿瘤控制。

要点

  • 低至中等外照射剂量可增强西妥昔单抗在肿瘤中的摄取。
  • 优化时序后,90Y-西妥昔单抗联合分割放疗较单纯放疗显著提高肿瘤控制。
  • 放疗前给予一定剂量可能改善药物摄取并支持PET示踪剂分层。

核心结论

  • 放射性标记治疗药物与临床相关分割放疗联合,具有显著改善治愈性治疗结局的潜力。

研究设计与样本

  • 临床前试验,使用FaDu头颈部鳞癌异种移植瘤小鼠模型。
  • 通过近红外标记西妥昔单抗活体光学成像纵向评估不同放疗剂量和时序下的抗体摄取。
  • 肿瘤控制概率实验采用分割放疗(30次,6周,每组8个剂量组)联合90Y-西妥昔单抗。

主要发现

  • 近红外标记西妥昔单抗成像显示,低至中等外照射剂量可增强抗体摄取。
  • 采用优化时序,90Y-西妥昔单抗(剂量在既往实验中未导致永久性肿瘤失活)联合放疗较单纯放疗显著提高肿瘤控制。

关键数值与推荐

  • 分割放疗方案为30次、6周,每组8个剂量组。

临床怎么用

  • 临床前结果提示,放疗前给予一定剂量可能改善抗体药物摄取。
  • 联合方案可能通过治疗中PET示踪剂实现患者分层与治疗个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Systemic molecular radiotherapy utilizes internal irradiation by radionuclide-labeled tumor-targeting agents with the potential to destroy (micro-)metastases. However, doses that are applicable in solid tumors do not reach the levels nessecary for tumor control. Thus, the combination of molecular and external radiotherapy is a promising treatment strategy, as enhanced tumor doses can be delivered with and without minor overlapping toxicities. Here, we combined a 90Y-labeled anti-EGFR antibody (Cetuximab) with clinically relevant fractionated radiotherapy in a preclinical trial using head and neck squamous cell carcinoma xenograft tumors. MATERIALS AND METHODS: To model 90Y-Cetuximab uptake for treatment schedule optimization, FaDu-bearing mice were injected with near-infrared-labeled-Cetuximab at different time points during radiotherapy with differing doses. Cetuximab uptake was longitudinally followed by in vivo-optical imaging. Tumor control probability experiments with fractionated radiotherapy (30 fx, 6 weeks, 8 dose groups/ arm) in combination with 90Y-Cetuximab were performed to test the curative potential. RESULTS: Imaging of near-infrared-labeled-Cetuximab uptake revealed that low to moderate external beam doses can enhance antibody uptake. Using the optimized schedule, combination of molecular and external radiotherapy using 90Y-Cetuximab at a dose that did not result in permanent tumor inactivation in previous experiments, led to substantially increased tumor control compared to radiotherapy alone. CONCLUSION: Our results indicate that combination of radiolabeled therapeutics with clinically relevant fractionated radiotherapy has a remarkable potential to improve curative treatment outcome. Application of some radiation dose prior to injection may improve drug uptake and enable patient stratification and treatment personalization via a corresponding PET-tracer during therapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Dietrich A, Andreeff M, Koi L, et al. Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial. Radiother Oncol. 2020. PMID: 33227356. doi:10.1016/j.radonc.2020.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。